Please login to the form below
Lexicon
This page shows the latest Lexicon news and features for those working in and with pharma, biotech and healthcare.
J&J’s Invokana first SGLT2 to show kidney disease benefits
Meanwhile Sanofi and Lexicon's Zynquista and Eli Lilly and Boehringer Ingeheim's market leader Jardiance are also both in renal outcomes trials, with their respective results expected by 2022.
Latest news
-
Success for AZ, setback for Sanofi in type 1 diabetes
Sanofi has been less fortunate with its US marketing application for Lexicon Pharma-partnered dual SGLT1/SGLT2 inhibitor Zynquista (sotagliflozin) alongside insulin in type 1 diabetes, however, as this was rejected ... Both AZ and Sanofi/Lexicon’s
-
CHMP backs Lynparza in breast cancer, Dupixent in asthma
There was also another positive opinion for Sanofi, this time for its Lexicon Pharma-partnered SGLT1/2 inhibitor Zynquista (sotagliflozin) as an oral add-on to insulin therapy to improve blood
-
FDA adcomm split on Sanofi’s type 1 diabetes drug
According to Lexicon, sotagliflozin is also being tested in type 2 diabetes with phase 3 results due this later year. ... Sanofi licensed rights to sotagliflozin from Lexicon in 2015 for $300m upfront and up to $1.4bn in development, regulatory and sales
-
FDA starts review of Sanofi’s oral type 1 diabetes drug
According to Lexicon, sotagliflozin is also being tested in type 2 diabetes with phase III results due in 2019. ... Lexicon exercised an option to co-promote the drug in the US for the treatment of type 1 diabetes last year.
-
Ipsen searches for new CEO after splitting top roles
Ipsen licenses the drug from Lexicon Pharmaceuticals and has rights outside the US and Japan.
More from news
Approximately 2 fully matching, plus 12 partially matching documents found.
Latest Intelligence
-
It’s not the end of the world, is it?
True and transparent value. The phrase ‘value-based healthcare’ entered the industry’s lexicon some years ago and there isn’t a pharmaceutical or medical technology company in existence that does
-
The first, my last, my everything
Because if the modern-day lexicon is anything to go by, the patient has become The First, the Last, the Everything for the global industry.
-
Communication is the key to unlocking the potential of immuno-oncology
Marje Isabelle, Founder and CEO, Fertile Matters. This means working with others to define a new lexicon for cancer care; helping healthcare professionals stay on top of the deluge of new
-
Six degrees of participation
Similarly, social listening is a great way of understanding the patient lexicon.
-
Asthma: beyond the blue and the brown
Indeed, it challenges the validity of the term ‘asthma’ in the modern day medical lexicon at all.
More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.
Latest appointments
-
Weekly comms appointments
In this newly created position, Pyati will develop a science-driven strategy, implement situational assessments and workshops and develop scientific platforms and lexicons.
-
Linda Law joins Advicenne as US VP, clinical development and med affairs
Law’s career has seen her serve in various positions for pharmaceutical companies including Procter &Gamble, Lexicon Pharmaceuticals and she has consulted on evaluation and development projects with Takeda, Confluence and
-
Onconova appoints Ajay Bansal as chief financial officer
Bansal (pictured) served as chief financial officer at Complete Genomics since May 2010, having previously held the role of chief financial officer and executive VP of business development at Lexicon Therapeutics. ... In addition to his prior roles at
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Mastering the precision medicine opportunity
While some might say that this change in lexicon is merely a progression in language, I would argue there are differences in the two approaches to identifying and treating patients.
-
Social Media and Health: the Cure or the Disease?
He is also changing the Facebook lexicon, swapping 'community' for 'connection' as the ultimate good. . .
-
The science of experience planning in pharma media
Experience planning is a popular phrase in today’s marketing lexicon. It focuses on how each interaction with a (potential) customer is an ‘experience’ and how to best plan this in
-
The Seven Cs Of Cross-Functional Brand Planning
Thinking about the plan, the process, how we go about it, the tools and lexicon. This is as much about language and definitions as it is about planning steps, stages, philosophy
-
Framing, provocation, and truth
It seems to be a word creeping steadily into the promotional lexicon of marketing research.
More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.
Featured jobs
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
-
Midweight Brand Planner
-
Up to £50, 000
- Head of Partnerships - Competitive - London
-
Competitive Salary Offered
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Senior Medical Writer
-
Salary TBC
Subscribe to our email news alerts
- Verily unveils next-gen trials alliance with Novartis, Pfizer
- Syncona launches another cell therapy company, Treg specialist Quell
- Keytruda monotherapy fails in triple negative breast cancer
- Moving annual total (MAT)
- Europe responding to gene therapy challenge, but picture remains fragmented
- Key success factor (KSF)
PMHub
Grace Communications
Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....
Latest intelligence
- Playing Mind Games
- To give a brief strong direction, we need to ascertain how the brand intends to win attention, how it will engage, what its call to action will be and how...
- PM Society Digital Award Finalists
- P&P are shortlisted for the ‘Craft in Film’ category at this year’s PM Society Digital Awards...
- The Exhibition Hall: Past, Present and Future
- As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Quick links
Infographics
